| Lisa M Radcliff, FNP | |
|
15700 Sw Greystone Ct, Beaverton, OR 97006-6011 | |
| (503) 203-1000 | |
| (503) 203-1010 |
| Full Name | Lisa M Radcliff |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 17 Years |
| Location | 15700 Sw Greystone Ct, Beaverton, Oregon |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467619320 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 200750073NP (Oregon) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ohsu Hospital And Clinics | Portland, OR | Hospital |
| Legacy Mount Hood Medical Center | Gresham, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Oregon Health And Sciences University/university Medical Group | 4880760107 | 1485 |
News Archive
In a major breakthrough for ovarian and uterine cancers, Yale researchers have defined the genetic landscape of rare, highly aggressive tumors called carcinosarcomas (CSs), pointing the way to possible new treatments.
International research co-led by professor Alejandro Maiche, of the Department of Basic, Evolutionary and Educational Psychology at the UAB, has put forward the hypothesis that the brain responds to the possibility that two objects might collide, in a different way to how it would react to two objects in movement with divergent trajectories.
Celera Corporation today announced that it has submitted a Premarket Approval Application (PMA) to the U.S. Food and Drug Administration (FDA) for its KIF6 Genotyping Assay, a new molecular In Vitro diagnostic (IVD) test designed to detect a marker for risk of coronary heart disease (CHD) independent of traditional risk factors and aid clinical evaluation when statin treatment is being considered.
OncoMed Pharmaceuticals, Inc., a company developing novel therapeutics that target cancer stem cells or tumor-initiating cells, today announced that the FDA has accepted an IND filing for OMP-18R5, which allows OncoMed to commence Phase 1 clinical testing.
The Healthcare Financial Management Association recently reviewed CDM Master, CDM Manager, CDM Enterprise, Charge Capture Audit, Comparative Rate Modeling, Strategic Pricing, KnowledgeSource, ABN Manager and Contract Manager using the Peer Review Process. After undergoing the rigorous review, these MedAssets' products have met the standards to receive the "Peer Reviewed by HFMA" designation.
› Verified 3 days ago
| Entity Name | University Professional Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376709535 PECOS PAC ID: 4880760107 Enrollment ID: O20080910000013 |
News Archive
In a major breakthrough for ovarian and uterine cancers, Yale researchers have defined the genetic landscape of rare, highly aggressive tumors called carcinosarcomas (CSs), pointing the way to possible new treatments.
International research co-led by professor Alejandro Maiche, of the Department of Basic, Evolutionary and Educational Psychology at the UAB, has put forward the hypothesis that the brain responds to the possibility that two objects might collide, in a different way to how it would react to two objects in movement with divergent trajectories.
Celera Corporation today announced that it has submitted a Premarket Approval Application (PMA) to the U.S. Food and Drug Administration (FDA) for its KIF6 Genotyping Assay, a new molecular In Vitro diagnostic (IVD) test designed to detect a marker for risk of coronary heart disease (CHD) independent of traditional risk factors and aid clinical evaluation when statin treatment is being considered.
OncoMed Pharmaceuticals, Inc., a company developing novel therapeutics that target cancer stem cells or tumor-initiating cells, today announced that the FDA has accepted an IND filing for OMP-18R5, which allows OncoMed to commence Phase 1 clinical testing.
The Healthcare Financial Management Association recently reviewed CDM Master, CDM Manager, CDM Enterprise, Charge Capture Audit, Comparative Rate Modeling, Strategic Pricing, KnowledgeSource, ABN Manager and Contract Manager using the Peer Review Process. After undergoing the rigorous review, these MedAssets' products have met the standards to receive the "Peer Reviewed by HFMA" designation.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lisa M Radcliff, FNP Po Box 3378, Portland, OR 97208-3378 Ph: (503) 601-7636 | Lisa M Radcliff, FNP 15700 Sw Greystone Ct, Beaverton, OR 97006-6011 Ph: (503) 203-1000 |
News Archive
In a major breakthrough for ovarian and uterine cancers, Yale researchers have defined the genetic landscape of rare, highly aggressive tumors called carcinosarcomas (CSs), pointing the way to possible new treatments.
International research co-led by professor Alejandro Maiche, of the Department of Basic, Evolutionary and Educational Psychology at the UAB, has put forward the hypothesis that the brain responds to the possibility that two objects might collide, in a different way to how it would react to two objects in movement with divergent trajectories.
Celera Corporation today announced that it has submitted a Premarket Approval Application (PMA) to the U.S. Food and Drug Administration (FDA) for its KIF6 Genotyping Assay, a new molecular In Vitro diagnostic (IVD) test designed to detect a marker for risk of coronary heart disease (CHD) independent of traditional risk factors and aid clinical evaluation when statin treatment is being considered.
OncoMed Pharmaceuticals, Inc., a company developing novel therapeutics that target cancer stem cells or tumor-initiating cells, today announced that the FDA has accepted an IND filing for OMP-18R5, which allows OncoMed to commence Phase 1 clinical testing.
The Healthcare Financial Management Association recently reviewed CDM Master, CDM Manager, CDM Enterprise, Charge Capture Audit, Comparative Rate Modeling, Strategic Pricing, KnowledgeSource, ABN Manager and Contract Manager using the Peer Review Process. After undergoing the rigorous review, these MedAssets' products have met the standards to receive the "Peer Reviewed by HFMA" designation.
› Verified 3 days ago
Amanda Hunt, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 4145 Sw Watson Ave Ste 350, Beaverton, OR 97005 Phone: 866-849-0692 | |
Mrs. Sherry Diane Davidson, PMHNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 10700 Sw Beaverton-hillsdale Hwy, Park Plaza West Bld 3 Suite 547, Beaverton, OR 97005 Phone: 503-643-0428 | |
Dr. Kathleen Anne Roberts, DNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2725 Sw Cedar Hills Blvd Ste 200, Beaverton, OR 97005 Phone: 503-352-6000 Fax: 503-352-6081 | |
Sherry L Sweeney, CPNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 15455 Nw Greenbrier Pkwy, Suite 111, Beaverton, OR 97006 Phone: 503-531-2323 | |
Ms. Hillary L Corson, APRN, PMHNP-BC Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 6600 Sw 105th Ave Ste 120, Beaverton, OR 97008 Phone: 971-245-1332 Fax: 503-641-5179 | |
Ms. Victoria Lynn Keyton, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 4510 Sw Hall Blvd, Beaverton, OR 97005 Phone: 503-644-1171 Fax: 503-643-7443 | |
Margie Nielsen, DNP, FNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 15950 Sw Millikan Way, Beaverton, OR 97003 Phone: 503-646-0161 Fax: 503-643-7459 |